Tranexamic acid in alcoholic gi bleed

Reading File

Checking Date & Time

Finding Sources

Searching PubMed

tranexamic acid AND gastrointestinal bleeding

Reading Article

Reading File

I now have sufficient high-quality data — including a dedicated RCT in cirrhosis patients (2024) and two major meta-analyses. Here's the synthesis:

Tranexamic Acid (TXA) in Alcoholic/Cirrhotic GI Bleeding

Mechanism Rationale

Patients with advanced liver cirrhosis (common in alcoholic liver disease) have a state of hyperfibrinolysis — both systemic and localized in the esophageal and gastric mucosa. TXA is a lysine analogue that competitively inhibits plasminogen-binding to fibrin, blocking clot dissolution. This makes it theoretically attractive in variceal and non-variceal bleeding in cirrhosis, where fibrinolytic activity is enhanced.

Key Evidence

1. HALT-IT Trial (high-dose IV TXA) — The pivotal negative trial

The largest RCT (n ≈ 12,009 patients with acute GI bleeding) tested 1g IV bolus + 3g over 24 hours of TXA vs. placebo.

No reduction in 28-day mortality (RR 0.99)
No reduction in rebleeding or need for surgery
Increased risk of VTE: DVT (RR 2.01, 95% CI 1.08–3.72), PE (RR 1.78, 95% CI 1.06–3.0), and seizure (RR 1.73)

This trial effectively ended the use of high-dose extended IV TXA in undifferentiated GI bleeding.

2. RCT in Cirrhosis Specifically — Kumar et al. 2024 (PMID: 38441903)

This is the most directly relevant trial for alcoholic/cirrhotic GI bleeding.

Population: 600 patients with Child-Pugh B/C cirrhosis presenting with UGIB
Intervention: TXA (likely low-dose) vs. placebo
Key findings:
- 5-day treatment failure: 6.3% (TXA) vs. 13.3% (placebo), p=0.006 — significant reduction
- Benefit was particularly pronounced at EVL (endoscopic variceal ligation) sites — failure to control post-EVL ulcer bleeding: 4.9% vs. 12.0%, p=0.005
- 5-day and 6-week mortality: no significant difference between groups
Conclusion: TXA reduces failure to control bleeding and reduces rebleeding in CTP B/C cirrhosis, especially at EVL sites — but does not reduce mortality.

3. Meta-Analysis — Dionne et al. 2022 (Crit Care Med, PMID: 34709209)

High-dose IV TXA: No benefit on mortality or bleeding; increases VTE and seizure (high certainty)
Low-dose IV or enteral TXA: Reduced rebleeding (RR 0.50, 95% CI 0.33–0.75) and need for surgery (RR 0.58), with moderate certainty — but no mortality benefit demonstrated

4. Meta-Analysis — Calderon Martinez et al. 2025 (PMID: 40029534)

TXA significantly reduced rebleeding overall (RR 0.81)
Mortality reduction in upper GI bleeding (RR 0.72, 95% CI 0.59–0.87) and when oral/IV routes combined (RR 0.56)
Important signal: TXA was associated with increased mortality in lower GI bleeding (RR 1.67) — use should be restricted to UGIB
No significant increase in thrombotic events overall (RR 1.30, 95% CI 0.75–2.23)
Need for transfusion: not significantly different

Summary Table

Parameter	High-dose IV TXA	Low-dose/Enteral TXA	TXA in Cirrhosis (UGIB)
Mortality	No benefit (HALT-IT)	No RCT mortality benefit	No benefit
Rebleeding	No benefit	Reduced (~50%)	Reduced (6.3% vs 13.3%)
Need for surgery	No benefit	Reduced (~42%)	Not reported
Thrombosis/VTE	Increased (DVT, PE)	Not clearly elevated	Not reported
Seizure	Increased	Not clearly elevated	Not reported
Current guideline stance	Not recommended	Uncertain	Potentially beneficial in EVL setting

Clinical Bottom Line

High-dose 24-hour IV TXA (HALT-IT regimen) is not recommended in GI bleeding — including cirrhotic/alcoholic bleeds. It increases VTE and seizure risk with no mortality benefit.
In cirrhosis (CTP B/C) with UGIB, the 2024 Kumar et al. RCT provides the best dedicated evidence: TXA reduces failure to control bleeding, particularly at post-EVL ulcer sites. However, this did not translate to reduced mortality.
The benefit appears most credible for upper GI bleeding (variceal or non-variceal) rather than lower GI bleeding, where harm signals exist.
TXA should not be used as a substitute for standard of care (vasoactive drugs — terlipressin/octreotide, antibiotics, early endoscopy, EVL/sclerotherapy). Its role, if any, is adjunctive.
Seizure risk is an important consideration in alcohol withdrawal patients, who are already at elevated seizure risk — high-dose IV TXA is particularly contraindicated in this context.

Key references:

Kumar M et al. Hepatology 2024 [PMID: 38441903] — RCT, TXA in cirrhosis UGIB
Dionne JC et al. Crit Care Med 2022 [PMID: 34709209] — Systematic review/meta-analysis
Calderon Martinez E et al. Indian J Gastroenterol 2025 [PMID: 40029534] — Comprehensive meta-analysis
Brenner and Rector's The Kidney — TXA in uremic/dialysis UGIB context

So what is the dose of tranexamic acid for alcoholic gi bleed

Based on the evidence already in context, here's a direct answer:

There is no established, guideline-recommended dose of TXA for alcoholic/cirrhotic GI bleeding — because TXA is not currently a standard-of-care recommendation for this indication.

However, from the trials discussed:

Doses Used in Key Trials

Trial	Dose	Outcome
HALT-IT (undifferentiated GI bleed)	1g IV bolus → 3g IV over 24h	No benefit; harm (VTE, seizure) — abandoned
Kumar et al. 2024 (cirrhosis UGIB — the positive trial)	Not specified in abstract	Reduced day-5 treatment failure; no mortality benefit
Older low-dose trials (meta-analysed by Dionne 2022)	1g IV or oral TID (enteral)	Reduced rebleeding ~50%, no mortality benefit

Practical Note

The only regimen with a positive signal in cirrhosis-specific UGIB came from the Kumar 2024 trial, and the abstract does not detail the exact dose. The low-dose regimens from the meta-analyses (typically 1g IV or 1g oral TID) are the only ones associated with potential benefit without the VTE/seizure harms seen with the HALT-IT high-dose protocol.

The HALT-IT dose (1g + 3g/24h) should be avoided — it was specifically tested in GI bleeding at scale and showed net harm.

Bottom line

Until the Kumar 2024 full paper clarifies the exact cirrhosis dose, and until a guideline formally endorses TXA in this setting, no specific dose can be recommended. If used off-label in cirrhotic UGIB after shared decision-making, low-dose strategies (1g IV bolus, not extended infusion) are the only ones with a plausible benefit-to-risk ratio — and this is particularly important in alcohol patients where seizure risk from high-dose TXA compounds pre-existing alcohol withdrawal risk.

Would you like me to retrieve the full text of the Kumar 2024 trial to find the exact dose used?

This is a shared conversation. Sign in to Orris to start your own chat.